BluKap launches BOBI50 after mapping 770 ocean-biotech companies

BluKap Ventures unveiled the inaugural BluKap Ocean Biotechnology 50 ahead of Climate Week NYC 2026, spotlighting 50 companies across health, food, agriculture, materials, aquaculture and climate tech. The list comes from BluKap ATLAS™, which tracks more than 770 ocean-biotechnology companies in 50+ countries and is designed to help surface a fragmented market that is becoming more commercial and global.

Why it matters: - Ocean biotechnology is spreading across multiple end markets, not just marine science. - BluKap’s new index is meant to make a fragmented sector easier to find, compare and finance. - The release signals growing investor attention to ocean-derived technologies tied to health, food, agriculture, materials and climate.

What happened: - BluKap Ventures announced the inaugural BluKap Ocean Biotechnology 50, or BOBI50, in Miami on Sept. 18, 2026. - The list highlights 50 companies that show the breadth and maturity of the global ocean-biotechnology ecosystem. - BluKap timed the release ahead of Climate Week NYC 2026.

The details: - BOBI50 was built using BluKap ATLAS™, the firm’s proprietary AI-powered intelligence platform. - ATLAS™ is designed to identify, research, analyze and track companies, technologies and assets derived from or inspired by ocean biodiversity. - ATLAS™ tracks more than 770 ocean-biotechnology companies across 50+ countries. - The platform also tracks 10 technology and end-market categories. - The database includes more than 650 investor entities. - ATLAS™ covers over 400 researched financing and acquisition events. - The platform also includes close to 1,000 documented investor participations. - BluKap said the data show an industry that is broader, more global and more commercially developed than conventional definitions of marine biotechnology suggest. - BOBI50 includes companies at Series A or later, including growth-stage, publicly listed and acquired businesses. - Earlier-stage companies tracked by ATLAS™ were excluded. - The index organizes companies by the technologies and biological assets they commercialize. - The result is a map of value creation across therapeutics, medical technologies, food, aquaculture, agriculture, materials and industrial applications. - BluKap said its release also reflects the firm’s view that ocean biotechnology matters to biodiversity and marine conservation, as well as to health, food, agriculture, materials and industrial production. - BluKap’s LinkedIn page is listed in the release for more information.

Between the lines: - Ocean biotechnology often disappears into other industry buckets once products reach market, which makes the sector hard to measure with standard classifications. - The company’s framing suggests BluKap wants BOBI50 to function as a market map, not a promotional watchlist. - The emphasis on later-stage companies points to a push toward commercial validation, not just scientific promise. - The data set also suggests capital is already flowing across a wide range of ocean-derived technologies, not a niche corner of biotech.

What's next: - BluKap is likely to use ATLAS™ and BOBI50 as sourcing and diligence tools for future investing. - The firm is positioning ocean biotechnology as a category that could keep expanding as more companies move from research to commercialization. - Expect more visibility around ocean biotech around Climate Week NYC and beyond as investors look for climate-linked health and industrial applications.

The bottom line: - BluKap is trying to define ocean biotechnology as a scaled, investable market — and BOBI50 is its first public proof point.